Shelton Wealth Management LLC Boosts Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Shelton Wealth Management LLC increased its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 77.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,969 shares of the medical equipment provider's stock after purchasing an additional 5,237 shares during the quarter. Shelton Wealth Management LLC's holdings in Lantheus were worth $1,071,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Signaturefd LLC grew its stake in Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 92 shares in the last quarter. UMB Bank n.a. boosted its position in shares of Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock valued at $47,000 after acquiring an additional 126 shares during the period. GAMMA Investing LLC raised its position in shares of Lantheus by 45.5% in the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider's stock valued at $51,000 after buying an additional 146 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Lantheus during the 3rd quarter valued at $25,000. Finally, CWM LLC grew its holdings in shares of Lantheus by 63.0% during the 3rd quarter. CWM LLC now owns 750 shares of the medical equipment provider's stock worth $82,000 after purchasing an additional 290 shares in the last quarter. 99.06% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on LNTH. StockNews.com downgraded Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. Truist Financial reaffirmed a "buy" rating and set a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. JMP Securities reiterated a "market outperform" rating and issued a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. Finally, The Goldman Sachs Group initiated coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a "buy" rating and a $143.00 target price on the stock. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $131.86.

Insider Buying and Selling at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of the firm's stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 2.10% of the company's stock.

Lantheus Stock Performance

Shares of NASDAQ LNTH traded down $0.11 during midday trading on Friday, hitting $91.47. 585,496 shares of the stock traded hands, compared to its average volume of 743,446. The business has a 50 day moving average price of $89.72 and a two-hundred day moving average price of $99.99. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $126.89. The company has a market cap of $6.36 billion, a PE ratio of 15.22 and a beta of 0.46.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.